BlackRock and QLS Advisors, a life sciences technology advisory firm, have partnered through BlackRock Systematic to develop data-driven investment ideas to help accelerate biomedical advances.
With $200 billion in assets, the BlackRock Systematic portfolios are structured to combine cutting-edge technology, scientific research and human insight to attain investment performance. The new partnership is said to leverage both QLS' and BlackRock's strengths in order to back public and private companies with the potential to create transformative therapies.
Founded by former quant-focused hedge fund manager Andrew Lo, QLS has developed proprietary technology for . . .
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.